The global robotic biopsy devices market size reached a valuation of USD 440.2 million in 2023 and is expected to grow at a CAGR of 9.3% over the forecast period. Robotic biopsy systems are leading the global market and held a share of about 59.8% in 2023. The market is expected to reach a valuation of around USD 1,072.3 million by the end of 2033.
Drivers in the Robotic Biopsy Devices Industry
Challenges for Companies in the Robotic Biopsy Devices Industry
Investment Opportunities in the Robotic Biopsy Devices Industry
Latest Trends in the Robotic Biopsy Devices Industry
| Attributes | Key Statistics |
|---|---|
| Global Robotic Biopsy Devices Market Estimated Size (2023) | USD 440.2 million |
| Projected Market Valuation (2033) | USD 1,072.3 million |
| Value-based CAGR 2023 to 2033 | 9.3% |
| Collective Value Share: Top 5 Countries | 50.5% |
The goal of a biopsy process is to confirm a cancer diagnosis by removing a tissue sample from a suspected lesion for a thorough pathological analysis. Traditional biopsy techniques rely on the radiologist manually inserting the needle. However, robotic systems add more stiffness and precision using a stable robotic manipulator than human hands.
They help the needle to retract more precisely while still preserving the tissue sample. Imaging methods, including computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, and other technologies, are used to locate lesions before the intervention. These are also used to guide the needle during the process by utilizing image feedback.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The robotic biopsy devices industry witnessed a steady CAGR of 5.8% from 2018 to 2022.
Prostate cancer is the second-most prevalent cancer and affects men, while breast cancer is one of the most common malignancies and the primary cause of cancer death among women. For high-risk patients to receive the best possible care or to prevent overtreatment in low-risk individuals, early and accurate identification of breast and prostate cancer is crucial.
Needle biopsy is the most reliable method for detecting breast and prostate cancer, as well as for determining how serious the stage of cancer is. Breast and prostate biopsies have a few similarities. They can be done with MRI or ultrasound guidance, and several core specimens are collected occasionally by using sample planning.
Although it is the simplest and fastest method, ultrasound navigation is not always accurate. Both MRIs and stereotactic biopsies are expensive and time-consuming procedures.
Using a robotic system for performing biopsies has the advantages of greater accuracy & precision, stability, superior hand-eye coordination, and lesser insertions. A robot could also improve the way humans analyze 3D pre-operative data as it does not develop fatigue or musculoskeletal conditions from carrying out the same task repeatedly for prolonged periods. These benefits will make surgeries quicker, less expensive, and less traumatic for the patient.
Additionally, advancements in healthcare infrastructure & institutional settings and the emergence of novel devices for minimally invasive interventions are expected to promote the adoption of robotic biopsy devices worldwide.
Owing to the aforementioned factors, the global robotic biopsy devices industry is expected to grow at a CAGR of 9.3% during the forecast period from 2023 to 2033.
Urgent Requirement of Surgical Precision
Image-guided surgery extensively makes use of surgical robots to simplify and improve device and instrument positioning. Any surgery requiring extreme precision benefits from robotic surgical tool placement systems.
By ensuring that surgical instruments are introduced at proper angles and depths, these technologies can streamline operating room procedures. Involuntary tremors frequently prevent individuals from achieving the level of precision required during surgical procedures.
Robotic positioning of surgical equipment has been proven to be effective in orthopedic and neurosurgical procedures. It is currently being investigated as a way to enhance the results of laser therapy, tumor resection, and biopsy procedures.
Thus, advancements in robot-guided instrument positioning will aid growth in the global robotic biopsy devices industry over the forecast period.
Principal Consultant
Robotic biopsy devices are highly advanced in terms of technology and can cater to image-guided minimally invasive procedures. But, the cost of equipment and set-up of such systems is higher than conventional healthcare equipment. Therefore, in emerging economies, extensive cost constraints may prevent product adoption among local healthcare institutions.
Moreover, for extensive pre-operative planning, there is a requirement for skilled professionals to interpret image-guided biopsy navigation. This proposes an additional capital expense for institutional settings, which may hamper growth.
Rapid Development of the Healthcare Sector in the United States to Drive Demand for Punch Biopsy Devices
The United States currently dominates the North America robotic biopsy devices industry, and it generated a share of about 34.0% in 2023. The country presents an extensive history of patenting for medical devices and is thus leading the robotic biopsy devices industry. The presence of a developed healthcare infrastructure and easy accessibility to advanced healthcare services among the general population would further support the country’s growth.
Key Players in the United Kingdom to Develop Novel Bone Marrow Biopsy Needles
The United Kingdom is set to hold a share of nearly 5.2% in the global robotic biopsy devices industry during the forecast period. The country marks the presence of several innovative market players, such as Medtronic, for robotic medical devices.
With the presence of various established key players in the country, the market for robotic biopsy devices in the United Kingdom is set to gain traction. Moreover, growing CE approvals for robotic biopsy devices will propel the industry.
Rising Prevalence of Lung Cancer in China to Aid Demand for Biopsy Forceps
China held around 5.2% of the share of the global market in 2023. In China, lung cancer is the most prevalent malignant tumor in terms of the number of new cases and the number of fatalities. To increase the survival rate of lung cancer patients, early detection and treatment are essential.
As chest CT examinations are becoming more widespread, new lung nodules are being identified. But, the final diagnosis ultimately requires verification by the gold standard test or pathological investigation. Therefore, a novel way of safe, precise, whole-lung diagnosis and therapy is urgently required in medical practice.
In March 2022, for instance, China completed the first domestic robotic-assisted trans-bronchial lung nodule biopsy. Similar developments are expected to boost growth in the China robotic biopsy devices industry.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Demand for Minimally Invasive Surgeries to Boost Sales of Automatic Biopsy Needle Systems
Robotic biopsy systems are expected to showcase high growth at a CAGR of 10.4% by the end of 2033. The segment held a share of around 59.8% in the global market in 2023, finds FMI. The growing installation of minimally invasive surgical robots around the globe has propelled sales of robotic biopsy systems.
Healthcare Professionals to Adopt Innovative Brain Biopsy Instruments
Brain biopsy held a revenue share of around 34.8% in 2023, and the segment is expected to display lucrative growth over the forecast period at a CAGR of about 12.3%. The emergence of novel medical devices owing to ongoing developments in the field of minimally invasive neurosurgery is set to aid growth. These developments would also lead to greater advancements in the assessment of cancer and disease progression.
Hospitals to Opt for Prostate Biopsy Devices to Provide Better Care
Hospitals held the highest market share of around 57.5% in 2023. With the growing prevalence of several types of cancer and the establishment of novel healthcare infrastructures, the hospital segment holds a considerable market value share among the other end users.
The global robotic biopsy devices industry is highly competitive, with the presence of a large number of key players. The majority of market participants are focusing on diversifying their product portfolios and introducing novel devices with innovative features at relatively low costs to attract a large consumer base.
Some of the recent industry developments are:
| Attribute | Details |
|---|---|
| Estimated Market Size (2023) | USD 440.2 million |
| Projected Market Valuation (2033) | USD 1,072.3 million |
| Value-based CAGR (2023 to 2033) | 9.3% |
| Historical Data Available for | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Market Analysis | Value (USD million) |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; and the Middle East & Africa |
| Key Countries Covered | United States, Canada, Brazil, Mexico, Argentina, United Kingdom, Germany, Italy, Russia, Spain, France, BENELUX, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC, and South Africa |
| Key Market Segments Covered | Product, Application, End User, and Region |
| Key Companies Profiled | Medtronic; Renishaw plc; iSYS Medizintechnik GmbH; Mazor Robotics; Biobot Surgical Pte Ltd; Medrobotics; Medtech SA |
| Report Coverage | Market forecast, brand share analysis, competition intelligence, DROT analysis, market dynamics and challenges, strategic growth initiatives |
The market is estimated to secure a valuation of USD 440.2 million in 2023.
The growth potential of the robotic biopsy devices market is 9.3% through 2033.
High cost of the research and development is likely to limit the market growth.
Rising emphasis on early detection and technological advancements are expected to drive sales of robotic biopsy devices.
Collaboration with research organizations and healthcare institutions may provide growth prospects for the market players.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product 5.1. Systems 5.2. Instrument & Accessories 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application 6.1. Brain Biopsy 6.2. Lung Biopsy 6.3. Prostate Biopsy 6.4. Others 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 7.1. Hospitals 7.2. Ambulatory Surgical Centers 7.3. Academic & Research Institutes 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. North America 8.2. Latin America 8.3. Western Europe 8.4. Eastern Europe 8.5. South Asia and Pacific 8.6. East Asia 8.7. Middle East and Africa 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16. Key Countries Market Analysis 17. Market Structure Analysis 18. Competition Analysis 18.1. Medtronic 18.2. Renishaw plc 18.3. iSYS Medizintechnik GmbH 18.4. Mazor Robotics 18.5. Biobot Surgical Pte Ltd 18.6. Medrobotics 18.7. Medtech SA 18.8. Accuray Inc. 18.9. Auris Health, Inc. 18.10. Hologic, Inc. 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Robotic Biopsy Devices Market
